Bio-Techne Reports Second Quarter Fiscal 2025 Results and Declares Dividend

Details

GAAP EPS was $0.22, while adjusted EPS increased to $0.42. The Protein Sciences Segment saw 8% organic revenue growth, and the Diagnostics & Spatial Biology Segment achieved 12% organic revenue growth. The Company also declared a cash dividend. Dr. Amy Herr was appointed to the Board of Directors, effective February 1, 2025.

Items reported

Exhibits (3)

About Bio-Techne Corporation

Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.